- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.02. | Boehringer Ingelheim and NIPER sign MoU on pharmaceutical research | ||
| 20.02. | Syngene and VivaMed collaborate on therapeutic programmes | ||
| 19.02. | Valneva's Lyme disease vaccine offers beacon of hope amid 2025 sales dip | ||
| 19.02. | J&J to build $1bn US CGT manufacturing site in Pennsylvania | ||
| 19.02. | Novartis enters licensing agreement with UNP for peptide therapeutics | ||
| 19.02. | MSD and Mayo Clinic team up to advance AI in drug development | ||
| 18.02. | FDA to review Moderna's flu jab on agency pivot | ||
| 18.02. | Novo expands injectable Wegovy offering with European higher dose approval | ||
| 18.02. | Evogene and QUT partner on AI-based cancer therapies | ||
| 18.02. | The China factor: US pharma group campaigns for increased competitiveness | ||
| 18.02. | J&J's Rybrevant Faspro gains FDA approval for new dosing in NSCLC | ||
| 17.02. | Pricing and reimbursement delays continue to impact biopharma revenue streams | ||
| 17.02. | Pharma companies venture further afield in search of R&D | ||
| 17.02. | Teijin and Aska Pharmaceutical to co-develop gynaecological drugs | ||
| 17.02. | ExCellThera secures German NUB Status 1 listing for Zemcelpro | ||
| 16.02. | Eli Lilly builds orforglipron cache to avoid previous GLP-1RA shortages | ||
| 16.02. | PTC pulls Translarna NDA after unfavourable FDA feedback | ||
| 16.02. | FDA issues complete response letter to Disc Medicine's bitopertin NDA | ||
| 16.02. | Immunic secures $400m fund to support commercial-stage development | ||
| 13.02. | European VC firms band together to tackle continent's lacklustre capital | ||
| 13.02. | Preclinical model drawbacks dampen UK innovation, ABPI report says | ||
| 13.02. | Ampersand Capital acquires Purna Pharmaceuticals | ||
| 13.02. | Amgen receives EC approval for Uplizna in generalised myasthenia gravis | ||
| 12.02. | Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head | ||
| 12.02. | Madrigal expands MASH pipeline in $4.4bn siRNA licensing deal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.